LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

30.83 2.32

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.61

Max

30.84

Pagrindiniai rodikliai
By Trading Economics
Pajamos	10M 32M
Pardavimai	-28M 215M
P/E Sektoriaus vid.	12.169 51.415
Pelnas, tenkantis vienai akcijai	0.786
Pelno marža	15.084
Darbuotojai	293
EBITDA	-2.8M 49M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+44.08% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-139M 1.7B
Ankstesnė atidarymo kaina	28.51
Ankstesnė uždarymo kaina	30.83

Naujienos nuotaikos

By Acuity

40%

60%

118 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-12 22:50; UTC

Uždarbis

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026-05-12 22:49; UTC

Uždarbis

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026-05-12 22:32; UTC

Uždarbis

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026-05-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026-05-12 22:57; UTC

Rinkos pokalbiai

Uždarbis

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026-05-12 22:26; UTC

Uždarbis

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure Interim Dividend A$0.50/Security

2026-05-12 22:24; UTC

Uždarbis

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026-05-12 22:19; UTC

Uždarbis

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026-05-12 22:13; UTC

Uždarbis

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026-05-12 22:11; UTC

Uždarbis

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026-05-12 22:11; UTC

Uždarbis

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026-05-12 22:10; UTC

Uždarbis

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026-05-12 22:08; UTC

Uždarbis

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026-05-12 22:07; UTC

Uždarbis

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026-05-12 22:05; UTC

Uždarbis

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

44.08% į viršų

12 mėnesių prognozė

Vidutinis 43.44 USD 44.08%

Aukščiausias 72 USD

Žemiausias 28 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

118 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.